Walleye Trading’s Dianthus Therapeutics DNTH Stock Holding History

Walleye Trading’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,143	Closed	-$81K	–	5437
2021 Q4	$81K	Buy	+1,143	New	+$115K	﹤0.01%	4487

Other funds holding DNTH

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Walleye Trading's DNTH Position: Q1 2022 in Review

Walleye Trading sold out of Dianthus Therapeutics (DNTH) in Q1 2022, closing a stake of 1,143 shares — an estimated $81K sold.

Walleye Trading first reported a position in DNTH in Q4 2021 and held it in 1 quarter. The position peaked at $81K in Q4 2021. 93 funds tracked by Wall St. Rank hold DNTH as of Q1 2022.

Walleye Trading reported no remaining Dianthus Therapeutics position as of Q1 2022 after selling out during the quarter.
Walleye Trading sold 1,143 Dianthus Therapeutics shares in Q1 2022, an estimated $81K.
Walleye Trading first reported a position in Dianthus Therapeutics in Q4 2021 and held it in 1 quarter.
Walleye Trading's Dianthus Therapeutics position peaked at $81K in Q4 2021.
93 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2022.

Based on Walleye Trading's 13F filing for Q1 2022, filed 16 May 2022.